Tag Archives: Diabetes

Diabeloop, a medtech firm that automates T1D treatment, presented new real-life results for its DBLG1® System at ATTD2022 in Madrid

PARIS, 28-Apr-2022 — /EPR HEALTHCARE NEWS/ — ATTD 2022 – Diabeloop, pioneer in therapeutic artificial intelligence for diabetes management, presents today new results from a real-life cohort in Germany. The data show a constant improvement in Time In Range (70-180 mg/dL) combined with a significant reduction of hypoglycemia.

DBLG1, Diabeloop’s hybrid closed-loop, showed improvement of Time In Range and reduction of hypoglycemic episodes which allows for better diabetes management and improved quality of life.

Time In Range: a continuous improvement, with even more people equipped

Presented today at ATTD, the latest data from DBLG1¹ real-life cohort demonstrates an increase of 18.4 percentage point in Time In Range (TIR 70-180 mg/dL) on 974 patients.

This significant gain confirms the constant improvement in Time In Range, a key indicator of glucose control, in people living with Type 1 diabetes equipped with DBLG1 System since the WP7² pivotal trial (+12 points), the commercial pre-launch³ (+16.7 points) and the results of the first real-life cohort in Germany4 (+17.1 points).

With several thousand people equipped, Diabeloop’s solution continues to increase the Time In Range and thus improves the associated clinical benefits, such as better glucose control, less complications and improved quality of life.

These significant performances confirm the ability of Diabeloop’s solutions to improve glycemic control of people with T1D, in real-life, in a less controlled environment than in hospital supervised studies.

DBLG1 users in Germany, included in the real-life cohort, benefit from basic support at initialization. This demonstrates the ease of use of Diabeloop’s automated and personalized insulin delivery system and its interface.

Prof. Pierre-Yves Benhamou comments: “From the first study – WP7 which showed an increase in Time In Range of 12 points, to today with +18.4 points following the European commercial launch of DBLG1, the continuous improvement of the TIR is significant. The results observed on the new real-life cohort of nearly 1000 people in Germany are very impactful, with patients with a baseline TIR (70-180 mg/dL) of 54.6% reaching 73% TIR in closed-loop with DBLG1. The other very positive result observed in this cohort is the significant reduction in hypoglycemia”.

A significant reduction of hypoglycemia combined with improvement in TIR

Associated with the increase in TIR, the retrospective data of the real-life DBLG1 cohort show a very significant reduction in time spent in hypoglycemia. Users of DBLG1 whose HbA1c was available at initiation spent only 0.9% of the time below 70 mg/dL and 0.1% of the time below 54 mg/dL5.

This variable has been constantly improving since the real-life WP72 study, which had already demonstrated a halving of the time spent below 70 mg/dL, a gain of more than 30 minutes less spent in hypoglycemia each day. More recently, the first real-life cohort in Germany demonstrated a time spent below 70 mg/dL at 1% and 0.2% below 54 mg/dL(4).

Thus, DBLG1 strongly contributes to reducing the short-term risks associated with hypoglycemia, such as discomfort, dizziness or even life-threatening situations. Diabeloop’s technology, based on artificial intelligence, allows an optimal diabetes management with less glycemic variations responsible for complications, and a life without interruption associated with the chronic disease.

“It is a great satisfaction to see that these new data extracted from an even larger cohort of patients show a simultaneous performance on TIR and reduction of hypoglycemia. Combined with the positive and very concrete feedback from the people equipped, this motivates us to go even further, to address more and more populations affected by diabetes” states Erik Huneker, CEO and co-founder of Diabeloop.

Testimonials: positive impacts in diabetes management, quality of life and mental burden

Since the commercial launch of its first solution in Europe last year, Diabeloop has received numerous feedback on the improvement of diabetes management and clinical benefits.

“I was skeptical about letting my diabetes be controlled by technology. But my diabetologist advised me to try it. My HbA1c dropped from 10% to 7% within two months. DBLG1 has improved my quality of life. I sleep better, I’m fitter, I’m very curious about what the next updates of DBLG1 will bring.” says Martin, living with diabetes for 45 years, equipped in Germany.

“My life has definitely changed with DBLG1. I have much less mental burden. I really noticed that I can have more time for other things and don’t have to concentrate on my diabetes all the time, as long as I take everything responsibly and estimate the carbs of my meals correctly. When I go to parties or some birthdays or other events, I know that DBLG1 always corrects me automatically. I’m really happy!” comments Eva, T1D using DBLG1 in Germany.

“DBLG1 has a “high-fat meal” feature that I use very often, even though I don’t eat that much fat but I don’t eat a lot of carbs either. It allows the delivery of biphasic boluses, adapted to the blood sugar level before meals and it works magically on me to avoid postprandial hyperglycemia!” says Stéphanie, equipped with DBLG1 in France.

Listen to all the testimonials in the first episode of the exclusive podcast Diabeloop Stories on Spotify : https://open.spotify.com/show/3GNcl…

Come and meet the Diabeloop team at ATTD, booth n°34 in the TechFair area.

CEO Erik Huneker and Pr Pierre-Yves Benhamou will present these results at Diabeloop session “AID pipeline perspectives & clinical outcomes” on Thursday, 28th April from 12:10 in the Exhibition Area.

About Diabeloop
Created in 2015, Diabeloop is a high-growth company that offers AI-based, personalized solutions to improve clinical outcomes for people with diabetes while relieving them of their constant mental burden. DBLG1 System, Diabeloop’s first medical device for automated insulin delivery (AID) and DBL-hu, its solution for highly unstable Type 1 diabetes management, are both CE-marked and being deployed in Europe.

A second round of financing of 31 million euros, concluded at the end of 2019, supported the international commercial rollout of DBLG1 iController and Diabeloop’s ambitious R&D program. Today, Diabeloop gathers the personality, passion, and skills of over 160 talented individuals who work hard to improve the quality of life for every person living with diabetes.

——————
References:

1 Real-life internal data (YourLoops data extract, from September 1, 2021, to December 31, 2021): 974 patients from Germany, who gave consent, equipped with DBLG1 System with Accu-Chek® Insight (Roche) insulin pump, with HbA1c available at initiation.

2 P.Y. Benhamou et al., «Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial», The Lancet Digital Health, Vol 1 (1), E17 – E25, 2019. DOI: 10.1016/S2589-7500(19)30003-2

3 C. Amadou et al., «Diabeloop DBLG1 Closed-loop system enables patients with Type 1 diabetes to significantly improve their glycemic control in real-life situations without serious adverse events», Diabetes Care 2021 Jan; dc201809. doi:org/10.2337-dc20-1809

4 Data from 152 patients equipped with DBLG1 System with Accu-Chek® Insight (Roche) insulin pump in Germany from April to September 2021 with available HbA1c at initiation, based on [Beck and al. 2019] equation for hb1Ac <=9% and hb1Ac>=6%”

5 Real-life internal data (YourLoops data extract, from September 1, 2021, to December 31, 2021): 1914 patients from Germany, who gave consent, equipped with DBLG1 System with Accu-Chek® Insight (Roche) insulin pump..

SOURCE: EuropaWire

Diabeloop to integrate insulin pens into its hybrid closed-loop system using a unique app

PARIS, 12-Apr-2022 — /EPR HEALTHCARE NEWS/ — Diabeloop, a pioneer in the field of therapeutic artificial intelligence, leverages the potential of its diabetes technology to enable the integration of insulin pens into its hybrid closed-loop system using a unique app. With DBL-4pen, Diabeloop offers new opportunities for personalized diabetes management for people with Type 1 and Type 2 diabetes, further advancing the quality of patient care.

Diabeloop opens a new segment in the insulin therapy market

Several tens of millions of people worldwide require insulin everyday. However, only 2 million of them1 are equipped with insulin pumps, because of their relative complexity and significant cost. Most diabetes patients in Europe and the U.S. on intensive insulin therapy are multiple daily insulin injections (MDI) pen users.

Diabeloop is developing a product for people living with diabetes who do not have access or want to wear an insulin pump. Using self-learning algorithms, DBL-4pen will bring most of the clinical improvement from DBLG1’s closed-loop to insulin pen users, while the overall cost will be significantly lower for the payer.

DBL-4pen: real-time mobile insulin dosing and telemedicine solution

People on multiple daily insulin injections using pens face the challenge of determining the correct amount and timing of insulin depending on individual blood glucose levels, physiology and lifestyle. To reduce hypoglycemia, risks of associated complications while lowering the mental burden of managing diabetes for patients using insulin pens, Diabeloop is developing a unique smartphone app that embeds its self-learning algorithm. The app is connected via Bluetooth® to a connected insulin pen and a CGM that measures blood glucose levels every 5 minutes.

On the way to more automation, DBL-4pen requires a minimal input from users. They only need to enter meals and physical activities into the app. DBL-4pen then automatically recommends the ideal insulin dose in real time, which can be delivered via the pen with no more calculation to do.

In addition, the measured data can be transmitted to the physician, healthcare providers or family members via YourLoops, the cloud based data visualization platform, if the patient so desires.

Strong partnerships to foster interoperability

DBL-4pen complements Diabeloop’s existing product line with another user-friendly and personalized solution that offers more control and customization possibilities regarding diabetes management.

“The integration of insulin pens into hybrid closed-loop systems is a substantial progress. Especially diabetes patients for whom pump therapy is a hurdle can benefit from this new solution. Moreover, diabetes therapy with insulin pens can be a viable solution for different healthcare systems,” said Prof. Hélène Hanaire of the University Hospital of Toulouse.

Diabeloop announces the extension of its partnership with BIOCORP, a French company specialized in the development and manufacturing of medical devices and connected healthcare solutions, to integrate Mallya®, their smart cap for insulin injection pens into Diabeloop’s technological environment.

This and other planned partnerships are expected to create new opportunities to bring Diabeloop’s interoperable technologies to people with diabetes who use insulin pens for their daily multiple injections.

“With DBL-4pen, we are able to bring the power of self-learning algorithms and connectivity to the majority of people who can not or do not want to wear an insulin pump. The combination of smart sensors for insulin pens with our self-learning algorithm gives us the opportunity to integrate a wide range of insulin pens into our hybrid closed-loop system in the future. Our goal is for this innovative solution to be compatible with almost all pens on the market,” said Erik Huneker, CEO and co-founder of Diabeloop.

Dynamic bolus insulin titration doses

DBL-4pen is currently a unique solution for MDI patients to dynamically titrate bolus insulin doses. Personalization is at the core of this solution because the app takes into account both entered meals and physical activities, as well as glucose trend, and uses the entire patient history to fine-tune bolus amounts based on the patient’s response to previous boluses.

“DBL-4pen offers a customized solution for MDI patients that can be integrated into hybrid closed-loop systems. Currently, we are in the process of launching a clinical trial in France to strengthen Diabeloop’s positioning in the insulin pen therapy market,” said Marc Julien, Chief Operating Officer of Diabeloop.

About Diabeloop
Created in 2015, Diabeloop is a high-growth company that offers AI-based, personalized solutions to improve clinical outcomes for people with diabetes while relieving them of their constant mental burden. DBLG1 System, Diabeloop’s first medical device for automated insulin delivery (AID) and DBL-hu, its solution for highly unstable Type 1 diabetes management, are both CE-marked and being deployed in Europe.

A second round of financing of 31 million euros, concluded at the end of 2019, supported the international commercial rollout of DBLG1 iController and Diabeloop’s ambitious R&D program. Today, Diabeloop gathers the personality, passion, and skills of over 160 talented individuals who work hard to improve the quality of life for every person living with diabetes.
——————
Reference:
1 2021 internal extrapolation based on Seagrove Partners and Simon-Kucher reports data

——————–
Meet Diabeloop at ATTD 2022 (27-30 April 2022, Barcelona, Spain) or contact us for further information at: partnership@diabeloop.fr

SOURCE: EuropaWire

Pr. Pierre-Yves Benhamou: The outcomes observed in 1,000 patients using Diabeloop DBLG1 are, indeed, very good and encouraging

PARIS, 28-Sep-2021 — /EPR HEALTHCARE NEWS/ —

Real-life data confirm clinical and pre-launch data: TIR significantly improved

Today, Diabeloop presents data¹ from a 1,000 patients equipped with DBLG1 System with Accu-Chek Insight insulin pump in Germany. One of the main insights unveiled is an overall Time in optimal glucose Range (70-180 mg/dL) of 73.4% for the whole cohort of patients.

When looking specifically at data² from patients whose HbA1c was available at initiation, it can be observed that Time In Range improved 17.1 percentage points. This result is consistent with results which have been previously published pre-launch³ showing an increase in Time In Range of 16.7 percentage points.

Hypoglycemia reduction a huge factor for an improved quality of life

Data also showed a significant reduction of time spent in hypoglycemia with Time below 70 mg/dL at 1% while time below 54 mg/dL was 0.2%. This outcome surpasses the targets of the 2019 International Consensus.

Feedback of people with diabetes and their caregivers have shown that reducing hypoglycemia is very important. In addition to the life-threatening risks associated with hypoglycemia, discomfort and a decreased quality of life weighs heavily on people experiencing it regularly.

Pre-launch patients
“It (diabetes) had a big impact on my professional life (…) because of my hypoglycemia.”
“I have almost eliminated lows (…), especially at night, which is important!”

Pr. Pierre-Yves Benhamou commented: “The 2019 International Consensus on Time in Range aimed at achieving >70% in range 70-180 mg/dL, <4% below 70 mg/dL and <1% below 54 mg/dL in the majority of people with type 1 diabetes. This means over 16 hours in target range and less than 1 hour below range. The outcomes observed in 1,000 patients using DBLG1 are, indeed, very good and encouraging.”

Patient satisfaction is high

In the 5 countries where DBLG1 System is currently available, feedback from equipped patients has been very positive about its impact on TIR and hypoglycemia, in addition to the system’s ease of use and enhancement of quality of life.

Public social media posts:
“87% TIR, no hypos”
“The result (related to sport): quite conservative but great. No hypo.”
“Very intuitive, little information needed to provide at initiation.”
“I am absolutely delighted. Sometimes I even forget that I have diabetes.
I let it (DBLG1) do the math and success shows.”

Erik Huneker, founder and co-CEO of Diabeloop, who will be presenting the data at EASD4 declared: “Looking at the great results and listening to patient feedback on real-life experiences with our system has been a great reward for our work, and encourages us to make the system even better going forward. We will be able to bring DBGL1 quickly to many more patients in Europe while we keep working on bringing more choices, more interoperability, and more solutions to people with diabetes”.

About Diabeloop
Created in 2015, Diabeloop is a high-growth company that offers AI-based, personalized solutions to improve clinical outcomes for people with diabetes while relieving them of their constant mental burden. DBLG1 System, Diabeloop’s first medical device for automated insulin delivery (AID) and DBL-hu, its solution for highly unstable Type 1 diabetes management, are both CE-marked and being deployed in Europe.

A second round of financing of 31 million euros, concluded at the end of 2019, supported the international commercial rollout of the DBLG1 iController and Diabeloop’s ambitious R&D program. Today, Diabeloop gathers the personality, passion, and skills of more than 100 talented individuals who work hard to improve the quality of life for every person living with insulin-dependent diabetes.

About DBLG1
DBLG1 is a self-learning algorithm that automates and personalizes the treatment of Type 1 diabetes. The therapeutic artificial intelligence contributes to reducing the heavy mental burden associated with this chronic condition. Hosted on a dedicated handset, it is connected to a continuous glucose monitor (CGM) and an insulin pump. It analyzes the data in real time, and decides whether to maintain current settings, adjust or stop basal insulin delivery to avoid a predicted low/high or deliver a bolus to correct a high.

YourLoops, Diabeloop’s data visualization platform allows patients to access data generated by DBLG1 and share them with his/hers healthcare team.

SOURCE: EuropaWire

Het DBLG1-algoritme: eenvoudige installatie, gebruiksvriendelijk, ontworpeyyn voor elk diabetes type 1 profiel

PARIJS, 2-Jun-2021 — /EPR HEALTHCARE NEWS/ — Vanaf het begin heeft Diabeloop innovatieve systemen ontwikkeld om de behandeling van diabetes type 1 te automatiseren en te personaliseren, waarbij altijd rekening wordt gehouden met de optiek van de patiënt. Het Franse bedrijf streeft ernaar autonomie te geven aan mensen die met diabetes type 1 leven en tegelijkertijd de gebruikerservaring te optimaliseren zodat behandeling van diabetes eenvoudiger en minder ingrijpend is. Het DBLG1-algoritme biedt een bevredigende, geautomatiseerde en gepersonaliseerde ervaring met minimale input van de patiënt.

DBLG1: eenvoudige installatie, gebruiksvriendelijk, ontworpen voor elk diabetes type 1 profiel

De zware mentale last op de schouders van mensen met diabetes type 1 verlichten, begint in de eerste fasen van de ervaring met DBLG1. Gebruikers hoeven maar 4 gegevens in te voeren in het allernieuwste DBLG1-algoritme voor een veilige, geautomatiseerde en gepersonaliseerde insuline-afgifte. In de opzetfase voeren gebruikers van DBLG1 hun lichaamsgewicht in, hun totale dagelijkse insulinedosis (TDD), hun gebruikelijke maaltijden (in grammen koolhydraten) en hun basale insulinebehoefte (alleen voor open-loop). Voor het Diabeloop-algoritme zijn geen ingewikkelde berekeningen nodig. Gebruikers hoeven hun maaltijdratio niet uit te zoeken, noch hun insuline gevoeligheidsfactor noch hun insuline actiecurve.

De 4 gegevens die de patiënt in de beginfase invoert, zijn voldoende voor het DBLG1 zelflerend algoritme om te functioneren, te berekenen en de insulinedosis zo nodig elke vijf minuten aan te passen.

“We hebben het DBLG1-algoritme zo ontworpen dat het zo eenvoudig mogelijk in gebruik is voor mensen met diabetes type 1 en gebruikers tegelijkertijd de gelegenheid hebben bepaalde parameters nauwkeuriger in te stellen afhankelijk van hun specifieke behoeften en/of leefstijl. Het algoritme houdt automatisch rekening met eventuele wijzigingen die mensen invoeren. Het DBLG1-algoritme optimaliseert de werking automatisch zonder dat de patiënt hier iets voor hoeft te doen. Wijzigingen verlopen op die manier heel soepel en worden vrijwel “onzichtbaar” voor de gebruikers van het systeem“ – vertelde Yousra Tourki, Head of Algorithms Design bij Diabeloop.

Naast de eerste input biedt het DBLG1 System ook de mogelijkheid aan mensen die met diabetes type 1 leven om de behandeling en beheersing van hun diabetes nauwkeurig in te stellen met behulp van aanpasbare instellingen zoals de agressiviteit van het algoritme, de grenswaarden van hypo’s en hypers en de streefwaarde van de glucosespiegel.

Nicole Wetzels, Trainer voor Roche Diabetes Care in Nederland en gebruikster van het DBLG1 System met Accu-Check Insight, vertelt: “Ik leef al meer dan 42 jaar met diabetes type 1 en ben een paar maanden geleden begonnen met het gebruik van het DBLG1 System met een Accu-Chek insulinepomp. De opzet was heel eenvoudig: de batterij in het apparaat doen, de handset opladen en maar 4 parameters invoeren. Het invoeren van een maaltijd is een van de weinige dingen die ik zelf moet doen en ook dat is heel simpel! Maar ik heb tevens de mogelijkheid het systeem te personaliseren door bepaalde instellingen aan te passen zoals de streefwaarde van de glucosespiegel of de grenswaarden voor de hypo … Met hele kleine acties heb ik hele goede resultaten. Dankzij dit AID-systeem hoef ik niet meer de hele dag bezig te zijn met het beheersen en behandelen van mijn diabetes. Het is net of mijn diabetes type 1 op vakantie is!”

DBLG1 AID-systeem: minimale input van de patiënt nodig

Om de bruikbaarheid van het DBLG1 System te beoordelen heeft Diabeloop een wetenschappelijk onderzoek uitgevoerd op basis van reële gegevens afkomstig uit de klinisch proef (1) die vóór de lancering vanhet systeem is gerealiseerd. Het doel was het analyseren van het aantal instellingswijzingen door mensen die het systeem in het dagelijkse leven gebruiken. In de eerste week dat patiënten het DBLG1 System gebruikten, voerden ze gemiddeld slechts 1.6 instellingswijzigingen uit (± 2.3), en maar 0.2 wijziging (± 0.5) in de laatste week van de proef na 11 weken gebruik.

De belangrijkste conclusie is dat in het dagelijkse leven, wanneer de gebruikers zich niet in een beheerste omgeving bevinden zonder specifieke medische follow-up en/of aanbevelingen voor instellingswijzigingen van hun zorgteam, de mensen uitgerust met het DBGL1 System minimale aanpassingen hoeven uit te voeren om te profiteren van een bevredigende, geautomatiseerde en gepersonaliseerde diabetesbehandeling.

Verdere wetenschappelijke analyse (2) toont de gebruiksvriendelijkheid aan van het Automated Insulin Delivery-systeem van Diabeloop. Deze analyse gaf aan dat in de eerste week, 50% van de mensen die het DBLG1 System gebruikten, geen instellingswijzigingen uitvoerden. Bovendien wijzigden meer dan 85% van de mensen uitgerust met het systeem geen enkele instelling gedurende de 8ste week van gebruik.

Dit bevestigt dat het zelflerend algoritme van Diabeloop vanaf de beginfase de behandeling van diabetes type 1 optimaliseert en minimale input van de patiënt nodig heeft om de vereiste ondersteuning te bieden.

Bernhard Gehr, arts en diabetoloog, Centrum voor Diabetes en Metabole ziekten, gespecialiseerde kliniek m&i Fachklinik Bad Heilbrunn, licht toe: “Ik gebruik het DBLG1 System met de Accu-Chek Insight insulinepomp. De opzet en de eerste handelingen zijn zeer eenvoudig. De eenvoud van de gebruikersinterface maakt snelle en makkelijke invoer van de benodigde informatie mogelijk. Ik ben echt onder de indruk van de prestaties van het DBLG1 System. Vanaf de eerste dag had ik een goede controle over mijn stofwisseling. Ik heb veel meer gemoedsrust aangezien ik veel minder aan mijn diabetes hoef te denken! Dit systeem vereist minder tot vrijwel geen micromanagement van mijn behandeling. Ik was aangenaam verrast over hoe goed het algoritme tijdens de eerste nacht functioneerde, met zo weinig input in de beginfase.”

Met DBLG1 beheersen mensen hun eigen diabetesbehandeling

Het DBLG1 System is gebruiksvriendelijk en kan gepersonaliseerd worden zodat mensen die met diabetes leven verschillende instellingen kunnen beheersen.

In het dagelijkse leven biedt het DBLG1 System mensen de mogelijkheid de aan te passen zodat insuline-afgifte bijgesteld wordt om een hypo of hyper te voorkomen. Een van de onderzoeken (3) van Diabeloop, gepresenteerd op ATTD 2021, onthulde dat een daling van de glucosespiegel streefwaarde over het algemeen een vergelijkbare daling van de gemiddelde glucospiegel tot gevolg heeft. Bijvoorbeeld, -10% van de glucosespiegel streefwaarde leidt tot -10% van de gemiddelde glucosespiegel.

In overeenstemming met de missie van Diabeloop om de zware mentale last op de schouders van mensen met diabetes type 1 te verlichten en hen een ongestoord leven te bieden, bevat het systeem een Zen-modus, ontwikkeld op basis van de ervaringen van patiënten. Deze modus verhoogt tijdelijk de doelwaarde van de bloedsuikerspiegel: om rustig naar de bioscoop te gaan of een vergadering bij te wonen zonder een verstorende hypoglykemie en de bijbehorende waarschuwingssignalen, kunnen gebruikers de Zen-modus aanzetten zodat hun glucosespiegel tijdelijk en voor een door hen ingestelde tijd verhoogd wordt.

Een persoon die het DBLG1 System met Accu-Check Insight insulinepomp gebruikt, vertelde: “Zen-modus is voor al die momenten waarop je je “veiliger” wil voelen: tijdens het autorijden, op school, tijdens een examen.”

Een wetenschappelijk onderzoek (4) geleid door Diabeloop en gepresenteerd op ATTD 2021, toonde aan dat 90 minuten na de activering van de Zen-modus, de impact op de gemiddelde glucosespiegel gestabiliseerd was zonder de hyperglykemie te verlengen.

De conclusie is dat, voor een tijd die door de patiënt wordt bepaald, de Zen-modus de gebruikers uit een hypo houdt en tevens een hyper voorkomt. De Zen-modus leidt tot een lichte verhoging van de gemiddelde glykemie met een zeer beperkte impact op de time-in-range.

Het eenvoudige gebruik van het DBLG1 zelflerend algoritme draagt bij tot een ongecompliceerde diabetesbehandeling en haalt een mentale last van de schouders van mensen die leven met deze chronische ziekte zodat ze ongestoord kunnen leven!

SOURCE: EuropaWire

Just For Diabetics Website Offers Hope for Pre-diabetics, Type 2 diabetics, and the Overweight

Research shows that the best time to take action to reverse pre-diabetes and type 2 diabetes is when you are at the stage of managing these conditions.

Vancouver, BC, Canada, 2018-Nov-06 — /EPR HEALTHCARE NEWS/ — November is world diabetes month. When people are diagnosed type 2 diabetic, the first line of defense is the use of prescription drugs in order to manage the diabetes. But what victims of pre-diabetes and type 2 diabetes are not aware of is that research performed by Just For Diabetics website founder, Ernest Quansah, shows that when patients are managing their pre-diabetes or type 2 diabetes, it is the best opportunity for them to reverse it and be weaned off the prescription drugs. The research results are evidence based. Many doctors and institutions now agree that this is the case. Recently, the University of British Columbia, in conjunction with Pharmasave, a drugstore chain, began offering obese people and type 2 diabetics a diet plan aimed at reversal of pre-diabetes and type 2 diabetes. The cost of their plan is $500 a month. The diet plan calls for no consumption of refined sugar, potatoes, fruit, fruit juices, sweet drinks of any kind, rice, bread, and consumption of cooked vegetables for lunch, cooked chicken breast for dinner and so on. Many of the participants are seniors, the overweight, or obese. After several thousand of dollars spent, many participants lose weight and their doctors take them off their diabetes drugs.

Quansah’s program includes a specialized diabetes exercise regime along with vitamin therapy and a carefully designed tasty menu cycle. He himself completely reversed his severe case of type 2 diabetes after compiling this program, which was the culmination of thorough research. This research included the advice of several physicians. Quansah, founder of Just For Diabetics and the author of Diabetics Journey says: “For several years, I have been educating people about how type 2 diabetes and pre-diabetes can be reversed through the program offered on my website. Now we see that one of Canada’s finest Universities and a drug store chain are doing the same.”

The website, justfordiabetics.com offers a free weight-loss program, a free diabetes reversal program, as well as an inexpensive paid program. The extensive program includes a full menu regime, exercise videos, tutorials, in addition to a cooking video demonstration, all for less than $180. Quansah wisely suggests that those on the program be monitored by their doctors.

Quansah’s research and findings have been published in the WebMD Diabetes magazine in the article “Secret recipe: How a Chef Cured His Type 2 Diabetes”, as well as on the WebMD website. There is hope for reversing pre-diabetes, type 2 diabetes (the type that does not require insulin injections,) and for overcoming being overweight.

“Misinformation about type 2 diabetes is rampant. For diabetics to heal, they need a complete change of attitude and way of thinking. This means, they should not just accept managing their condition, but rather, understand that they can be healed. Further, complacency about pre-diabetes leads to full-blown diabetes, which can lead to heart disease, blindness, liver failure, impotence, limb amputations and early death,” cautions Quansah.

Quansah has been asked to be guest speaker at the Diabetes and Healthcare Conference being held in Helsinki, Norway, in November 2018 and to be keynote speaker at the Diabetes Care Conference being held in Malaysia in May of 2019. His speech topic will include how to help diabetics heal and resultantly reduce healthcare costs.

Via EPR Network
More Healthcare press releases

How Type 2 Diabetes Can Be Cured

VANCOUVER, B.C., May-31-2018 — /EPR Healthcare News/ —  The mission of the International Diabetes Federation (IDF) is to promote diabetes care and cure worldwide. Type 2 diabetes, once thought only to afflict African descends, other minorities, and the less educated, is now an ignored pandemic afflicting over 450 million people from diverse academic backgrounds and races, worldwide. Health Department budgets allocated for managing diabetes in developed nations each year is staggering; far exceeding the GDP of most other countries. In a new book titled Diabetic’s Journey, diabetes survivor and expert, Ernest Quansah, demystifies how type 2 diabetes can be cured.

In his book, Quansah chronicles circumstances that led him to crave and heavily indulge in sugar, one day awaking to find a sticky, whitish substance in the corners of his eyes and on his tongue. Upon reviewing Quansah’s blood tests, his doctor used these words: “Do you know the danger you have put yourself in? You are not far from going into cardiac arrest. The whitish substance is sugar build-up in your body trying to find a way out.”

Quansah’s research uncovered two lifesaving pieces of information:

  1. Type 2 diabetes is caused by consumption of refined sugar; a fact confirmed by Dr. Sanjay Basu, Ph.D., of Stanford University.
  1. Natalia McInnes of McMaster University, type 2 diabetes cure researcher, stated that type 2 diabetes can be reversed  and cured in four months.

Said Quansah, “My doctor supported Dr. McInnes’s findings when he said to me: ‘Type 2 diabetes is cured using several approaches all working together. The diabetes is cured if it does return two years after reversal.’ Reversing type 2 diabetes costs less than $200.00 per diabetic, a fraction of what is spent each year managing diabetes for the rest of one’s life. This is not taking into account the added cost of the onset of other diseases resulting from the diabetes. Best of all, the victim’s life will be saved when he or she is cured. One becomes type 2 diabetic when sugar builds up in the body and converts into fat. Some of the fat finds its way into the bloodstream. It coats red blood cells preventing them from absorbing sugar and transporting it to the muscles to be used as energy. The pancreas still works; however, the insulin it secretes is not able to transport the excess sugar. The excess sugar buildup causes heart disease, kidney failure, nerve damage, blindness, etc.: Diabetes simply forecasts these pending diseases. The solution is simple. To reverse type 2 diabetes, the sugar buildup in the body and the fat coating the cells must be expelled, allowing for normal cell function.”

Quansah developed:

  1. A customized weight-reducing menu cycle
  2. A customized fat and sugar burning exercise routine
  3. A vitamin/supplement regime to protect the heart

When asked about his own response to his program, Quansah said, “Within a month of applying the above factors, my energy level surged. My doctor ordered another blood glucose test. ‘Look at your test results,’ Dr. Robinson said. ‘Congratulations. You are no longer a diabetic.’ My life was saved. I told him that I must write a book to help other diabetics. He replied, ‘that’s an excellent idea.’”

Quansah’s book, Diabetic’s Journey, is endorsed by a professor of diabetology and medicine. Reviewers gave his book a rating of 8.8/10.

Proof that type 2 diabetes can be reversed: WebMD, the leading healthcare information provider to doctors and consumers, interviewed Quansah and published an article about his diabetes cure methodology in WebMD Diabetes Fall 2016 issue, page 19, and on their website. The article was titled, Secret recipe: How a Chef Cured His Type 2 Diabetes . Additionally, Clyto Access contacted him to produce a video presentation on How Type 2 Diabetes Can be Cured to be presented at the International Diabetes and Degenerative Disease conference. His paper titled, The Case Against Managing Type 2 Diabetes is posted on Academia.edu and has been viewed and downloaded by researchers worldwide.

Quansah’s book’s subtitle, How Type 2 Diabetes Can be Reversed and Cured, amplifies what doctors say. Quansah says, “The mission of the Just for Diabetics website is to promote diabetes care and cure by offering pre-diabetics and type 2 diabetics the tools to reverse and cure themselves. Proceeds provide funding to humanitarian efforts and for developing products for diabetics.”

###

Ernest Quansah is available for interviews.

Email: ernestq@ernestquansah.com

Cell: 1-778-229-8049

Diabetic’s Journey is available from:

Amazon: ISBN- 978-0994767042

Website: https://justfordiabetics.com

Experimentica Ltd. licenses Akimba mouse model for diabetic retinopathy from Lions Eye Institute, Australia

Kuopio, Finland, December 18, 2014 — /EPR HEALTHCARE NEWS/ — The Lions Eye Institute (LEI) and Experimentica Ltd., a global ophthalmic contract research organization (CRO) announced today that they have entered into an exclusive license agreement for the Akimba mouse model for diabetic retinopathy for contract research. The license agreement was facilitated by Bio-Link Australia, a life sciences commercialisation company.

About Lions Eye Institute

The Lions Eye Institute (LEI) is the leading ophthalmic research institute in Australia. LEI employs scientists, clinicians and support staff to conduct first class scientific research into blindness and incorporates one of Australia’s largest ophthalmic practices. The Department of Molecular Ophthalmology (DMO) was founded by Professor Rakoczy in 1989 with the aim of using technological breakthroughs for the treatment of blindness. The Kimba mouse model have been successfully used in preclinical trials for a DMO developed gene therapy based treatment for wet-AMD that reached Phase I/II stage (www.lei.org.au;www.avalanchebiotech.com).

About Experimentica Ltd.

Experimentica Ltd. is a preclinical contract research organization (CRO) dedicated to develop and provide ocular disease models. Experimentica Ltd. is a global company and the largest ophthalmic CRO in Northern Europe, striving to provide scientific excellence by relying entirely on in-house expertise. Experimentica Ltd. is headquartered in Kuopio, Finland with offices in Tampere, Finland and Kansas City, MO, USA. For more information, visit www.experimentica.com.

About Bio-Link
Bio-Link Australia Pty. Ltd. is a life sciences commercialisation company which facilitates partnerships in the biopharma, medical device and diagnostic industries. Bio-Link has offices in Sydney and Melbourne, Australia, and clients including leading Australian and international biotechnology and medical device companies and medical research institutions. For more information, visit www.bio-link.com.

Contact details:
Experimentica Ltd/Giedrius Kalesnykas,
Microkatu 1, P.O.Box 1188,
70211 Kuopio, Finland.
E-mail: info@experimentica.com,
www.experimentica.com

Media enquiries:

For Experimentica:
Giedrius Kalesnykas, Ph.D.
Phone: +358 (50) 379-0275
US Toll Free: +1 (844) 393-4393
Email: gk@experimentica.com


For the Lions Eye Institute:

Francesca Robb
Communications and Media Officer
Phone: (+61 4) 09 102 556
francescarobb@lei.org.au

Via EPR Network
More Healthcare press releases

In support of World Diabetes Day, Harvey Norman’s Connected Fitness team research reveals that 280 Australians develop diabetes every day

In support of World Diabetes Day (14 November), Harvey Norman’s Connected Fitness team carried out a detailed research project to uncover the extent of Australia’s type 2 diabetes problem. The worrying results indicate that an estimated 1.7 million Australians suffer from type 2 diabetes today, with up to half of these cases currently undiagnosed. Reports from The World Health Organisation indicate that the total number of diabetic Australians is expected to increase to 3.3 million by 2031, creating a healthcare timebomb for the country. An infographic to visually represent the results has been specially commissioned and can be found on the Harvey Norman website.

Diabetes can significantly impact the quality of life and life expectancy of its sufferers. Some of the potential health complications caused by the disease include kidney damage, heart disease and stroke, loss of vision, and foot ulcers leading to limb amputation. The long term impacts on the life of the sufferer, and on healthcare costs for the country, are significant. However, it is known that up to around 60% of cases of type 2 diabetescould be prevented.

Key steps that can be taken to help prevent the development of this killer disease include eating a healthy diet, cutting out tobacco, keeping alcohol consumption within sensible limits and taking regular exercise. Walking, running and cycling are all great forms of exercise that enable people to work at their own pace and can easily be carried out in the home using treadmills and exercise bikes. Harvey Norman’s Connected Fitness team are on hand to provide help and advice on suitable fitness equipment and tools that can make it easy for people to increase their levels of activity and monitor their progress.

Harvey Norman’s Daniel Hosford, says: “World Diabetes Day should be an important date in everyone’s diary. Harvey Norman understands the importance of following a healthy lifestyle in order to protect against this debilitating disease and we’d like to do our bit to support the aims of the day. Our Connected Fitness team are happy to help our customers find the right equipment to help them take part in a healthy level of exercise, and our range is also available to purchase online for those customers who don’t have a store nearby. ”

Via EPR Network
More Healthcare press releases

Chris Smith, The Diabetic Chef Joins “Living Well” Diabetes Eduaction Cruise Hosted by Diabetes Daily Post (DDP)

Novi-based Diabetes Daily Post announces on June 29, 2012 that it has join hands with Chris Smith to educate diabetes patients on nutrition, diet, and diabetes cooking on Royal Caribbean Cruise which sails on January 7, 2013 for a 6 day Caribbean cruise. Other participants are Jorge Prada, MD, an Educator and Diabetes Researcher, Susan Sloane Pharmacist and Certified Diabetes Educator, a member of American Diabetes Association board of director and Charles Liu, Clinical Pharmacist with special interest in Type 2 Diabetes. With Chris Smith’s participatiion, DDP’s education program lands itself as one the most comprehensive and dynamic diabetes education program offered in the North America. The participants will receive a broad and comprehensive education including a diabetes-exercise session and onboard two-mile fun walk for diabetes to raise funds for the American Diabetes Association and go home with usable recipes and cooking methods to control their diabetes better.

“Diabetes is a cause for many other metabolic diseases such as heart and vascular diseases and stroke. Complications include loss of eye sight, kidney failure and amputation. Recent study showed a 62% reduction in diabetes-related health care costs if a comprehensive interdisciplinary diabetes education is implemented. Diet control is one of the most important facets in controlling diabetes and this is often neglected or ignored. We are very fortunate to have Chirs onboard to drive home on this point. Chris is known as one of the most caring and talented chef. He educates and motivates: he is completely at home with the subject of type 1 diabetes and type 2 diabetes. His passion comes from being a diabetic patient himself.” says Charles Liu R.Ph, MBA, DDP’s Cruise Education Coordinator and spokesman.

The Diabetes Daily Post a/k/a/ www.diabetesdailypost.com based in Novi, Michigan was created in 2011 to educate, enrich, and expand the knowledge of Diabetes. Its goal is to keep you informed about the latest news and drug innovations, provide health tools for diabetes management, motivate with triumph personal stories and talk about key opinion leaders who have worked on the elusive cure for Diabetes. The Diabetes Daily Post offers its “Living Well” Diabetes Education program both on cruises and in major cities.

Chef Chris is a Certified Executive Chef with over 20 years experience in the culinary field. With his focus on healthy cuisine, Chef Chris is an authority on diabetic nutrition and food preparation. He has been featured in TIME Magazine, USA Today, CNN, Web MD, Southern Living magazine. National television appearances include “DLIFE” and “Taking Control of Your Diabetes”. Chris is Novo Nordisk“Diabetes Academy” National tour speaking to both public and corporate audiences on the importance of cooking healthy and maintaining a healthy lifestyle. Chef Chris’s cookbook: The Diabetic Chef’s Year Round Cookbook along with Cooking with The Diabetic Chef, are published by The American Diabetes Association. Both cookbooks provide simple tips, cooking techniques and a wide range of easy to prepare recipes the whole family will enjoy!

If you’d like more information about this topic, please consult
www.diabetesdailypost.com Search cruise or click
http://diabetesdailypost.com/type-2-diabetes-travel-tips-how-to-book-a-cabin/

Via EPR Network
More Healthcare press releases

Lloydspharmacy Unveil New Health Web Tool

Lloydspharmacy has launched a new web tool which allows people to work out how many of their work colleagues is carrying a sexually transmitted disease, drinks too much alcohol or is depressed.

The ‘Chances Are…’ Health Calculator, developed by community pharmacy chain Lloydspharmacy, is designed to stimulate debate and make health risks more relevant by applying nationally representative data to the workplace.

“People have become rather de-sensitised to national statistics,” said Andy Murdock, Governance and Pharmacy Relations Director of Lloydspharmacy. “When you hear that 15 per cent of the population is in danger of developing diabetes, it’s a bit meaningless, but when you discover, for example, in an office of 50 people, eight will be pre-diabetic and 10 of the men will experience some form of erectile dysfunction after turning 40, you’re more likely to sit up and take notice.

“That’s why we have launched this online tool. We hope it will be used in workplaces up and down the country, get people talking and encourage them to think about their own risk factors and what they can do to reduce their chances of developing lifestyle related diseases.”

The calculator asks visitors to provide information about the type of workplace they are employed in, along with the gender split and age profile of their workmates. It then raids its database to calculate how many colleagues have Chlamydia, how many men are likely to develop erectile dysfunction, how many are likely to suffer a stroke, how many have raised cholesterol, how many are hazardous drinkers and much more.

In many cases information is provided about the condition or the issue and guidance is provided about what can be done to reduce risk factors.

Via EPR Network
More Healthcare press releases

Lloydspharmacy Warns Not To Rely On Swine Flu Jab To Protect Against Winter Flu

Lloydspharmacy has warned that the number of people protecting themselves against seasonal flu has fallen this year, possibly the result of a misguided belief that the swine flu jab will protect against winter flu.

As of 6th November there had only been a 54% uptake in people aged 65 and over, and only 27% uptake by people aged 55 – 65 to date, of the seasonal flu vaccine. Opinium Research conducted for Lloydspharmacy among 2007 UK adults 4 – 6th November 2009. This is a big reduction compared with the 73.5% uptake in 2008 by over the 65s and 73.9% in 2007 (The Fifty-sixth World Health Assembly).

According to research conducted by Lloydspharmacy almost 40% of people wrongly believe that the swine flu vaccine will also protect them against seasonal flu. Even more worryingly, more than half (52%) of the over 65s – one of the groups most vulnerable to winter flu – thought they would be protected against both strains if they had had the swine flu vaccination.

People over the age of 65 qualify for a free NHS seasonal flu vaccination as do people with conditions such as diabetes, asthma, heart disease, lung disease, kidney disease, chronic liver disease, lowered immunity due to disease or treatment (such as steroid medication or cancer treatment) or removal of the spleen, or if they are a resident of a nursing or residential home. Anyone who is the main carer for an elderly or disabled person and whose wellbeing may be put at risk if the carer falls ill, is also eligible for a free vaccination from their GP.

Others who are not eligible for free NHS treatment can still have an online consultation with a doctor and be vaccinated at high street pharmacies for a fee of£5, with Lloydspharmacy offering a seasonal flu vaccination service in 260 of its pharmacies.

Seasonal flu is responsible for the deaths of about 8,000 people in the UK a year and tends to affect the more vulnerable or elderly people. Last week the European Centre for Disease Prevention and Control forecast that the swine flu and seasonal flu strains could claim 40,000 lives each across Europe this winter.

The World Health Organisation has urged national governments to put in place plans to vaccinate at least 75 per cent of people most at risk of seasonal flu by 2010.

“Whilst there is still time for vulnerable people to get themselves protected before late November (when the Winter flu season reaches its peak) we would certainly expect to see a higher uptake by this time of year,” said Clare Kerr, head of clinical services at Lloydspharmacy.

Via EPR Network
More Healthcare press releases

A New Study Presented At The 26th Annual Meeting Of The American Society For Metabolic & Bariatric Surgery Confirms That Laparoscopic Gastric Banding Surgery Results In An 83% Improvement Or Remission Of Type 2 Diabetes

A new study presented at the 26th Annual Meeting of the American Society for Metabolic & Bariatric Surgery confirms that laparoscopic gastric banding surgery (LAGB) results in sustained weight loss as well as an 83% improvement or remission of Type 2 diabetes.

A New Study Presented At The 26th Annual Meeting Of The American Society For Metabolic & Bariatric Surgery Confirms That Laparoscopic Gastric Banding Surgery Results In An 83% Improvement Or Remission Of Type 2 Diabetes

Laparoscopic adjustable gastric banding surgery (LAGB) not only results in sustained weight loss for morbidly obese patients, but it also provides an improvement or remission of Type 2 diabetes in 83% of the patients.

This news, the results of a new study, was presented at the 26th Annual Meeting of the American Society of Metabolic & Bariatric Surgery (ASMBS). The event was held in Dallas, Texas, and Slimband was there to learn first-hand about the ground breaking study.

To date, this is the largest long-term study on the impact of gastric banding on diabetes. This study strongly suggests that there is a definite connection between diabetes and morbid obesity. The study noted that the patients who achieved and maintained a significant weight loss also realized the greatest remission of diabetes in a shorter time frame.

The study included 95 participants who ranged in age prior to surgery from 21 to 68 years, with an average BMI (Body Mass Index) of 46. Researchers from New York University (NYU) Medical Center conducted the study from January 2002 through January 2004. Approximately 88% of the patients were taking oral medications to control their diabetes and about 15% were using insulin. On average, the patients had been diagnosed with diabetes about 6 ½ years before surgery.

As routine follow up to the surgery, the patients’ weight was monitored and blood tests were done. During the first year, researchers followed each patient on a monthly basis, and during the second year the follow-ups were every three months.

After that, the follow-ups were annual unless more frequent visits were needed. At the end of the five-year follow-up period the data clearly showed that in about 40% of patients, diabetes was in remission and in about 43% it was improved, which resulted in a combined improvement/remission rate of 83%.

The incidence of diabetes and obesity is on the rise and that has resulted in several studies for effective methods for sustaining weight loss and for diabetes remission. Bariatric Surgery has been shown to be an excellent option for the treatment of morbid obesity as well as a way to improve Type 2 diabetes.

ASMBS is a non-profit organization that works to progressively move forward in the science of gastric banding surgery.

Slimband® is one of the largest and most respected Toronto Weight Loss Surgery and treatment centers in Canada. Slimband® specializes in reversible laparoscopic weight loss surgery with a unique aftercare program that includes nutritional counseling, coaching, and fitness programs and fills adjustments. Clients benefit not only from safe, fast weight loss but also experience increased energy levels and the control or elimination of weight-aggravated conditions like heart disease, high cholesterol, and type 2 DiabetesSlimband® has helped more than 3,000 patients fulfill their dreams of looking and feeling their best.

Via EPR Network
More Healthcare press releases

Allalternativemedicine.Com – One Of The Popular On-Line Stores For Natural Herbal Remedy

Alternative Medicine. Natural Remedies is online about a year. Since then the website becomes more and more popular. Natural herbal remedies are gaining more popularity in the United States today. More then 80 million of Americans acknowledge alternative medicine remedies for a variety health conditions versus traditional medicine.

All products presented on the website are made in precise therapeutic dosage from natural herbal ingredients. Comprehensive information on diagnosis, symptoms, and natural remedies are also presented on the website.

The natural herbal remedies for diabetes, insomnia, body cleansing and detoxification, weight loss, anxiety, panic attacks, depression, natural body and hair products, pain relief, immune system strengthening, cold/flu, and many others can be purchased on Allalternativemedicine.com. All products are made in Israel and kosher, carefully picked and based on positive impact and customers reviews.

The number of visitors in Allalternativemedicine.com has been growing steadily since its start in 2008. Allalternativemedicine.com uses effective, convenient and simple way to present useful information and products to visitors.

Visitors can easily find the products or the information they are looking for. It is just one click away form the main page. Visitors can feel confident using the All Alternative Medicine products and natural remedies.

You can visit the shopping site at the following web address: http://www.allalternativemedicine.com.

Via EPR Network
More Healthcare press releases

Recent Research Published By The American Journal For Medicine Showed 87% Of Diabetics Either Saw A Complete Cure Or Improvement After Weight Loss Surgery

As the focus on the nation’s expanding waistlines grows, medical experts now believe that weight loss surgery can completely eliminate all types of Diabetes.

The UK’s number one weight loss surgery provider, The Hospital Group, has seen outstanding long-term results for its gastric band patients over the last three years. Of the 106 gastric band operations performed in January 2007, the total weight loss was a massive 300 stone. Obesity is the main risk factor for Diabetes, so sustained weight loss on this level goes a long way towards fighting the condition, which affects 2.5 million people in the UK, according to Diabetes UK.

The research published by the American Journal for Medicine showed that following obesity surgery, 87% of diabetics either saw a complete cure or improvement.

David Ross, Chief Executive of The Hospital Group, said: “More and more people are choosing to have obesity surgery with The Hospital Group and it’s fantastic because people see results so quickly, which gives them the get up and go to live healthier lifestyles – some free from Diabetes. You wouldn’t think it, but Australia is the gastric band capital of the world. Their government recognises the long-term savings it can make by funding obesity surgery on their national healthcare system – and in the same way, obesity surgery in the UK is saving the NHS money by curing Diabetes patients, which is currently costing the NHS £1m an hour.”

The huge surge in demand for obesity fighting treatments such as Gastric Bands, Balloons and Bypasses from The Hospital Group has more than doubled in the last year, rising from 111 operations in February 2008 to 225 in the same month in 2009. Continuing the trend, enquiries into gastric band surgery have risen by almost 25% from 727 in February 2007 to 963 in February 2009. Health-conscious surgery-seekers in February 2008 made 815 enquiries into The Hospital Group’s obesity surgery.

The Hospital Group is committed to providing the very highest standards and all procedures are performed by an expert medical team in state-of-the-art facilities that are second to none. Since The Hospital Group was established in 1992, it has grown from a small pharmaceutical company to one of the UK’s foremost cosmetic surgery providers, and the same high standards remain to this day. For further information of The Hospital Group’s range of gastric procedures, surgery-seekers should visit the website www.thehospitalgroup.org or call our patient care coordinators on 0845 762 6727.

Via EPR Network
More 
Healthcare press releases